Table 1 Baseline demographic variables of the 99 patients with active Crohn’s disease who were assigned to intensive GMA or to weekly GMA in this study
Demography | Intensive GMA | Weekly GMA | P value |
|---|---|---|---|
(n = 54) | (n = 45) | ||
Male gender - n (%) | 34 (63.0) | 24 (53.3) | 0.4133 |
Age, year | 31.5 [24.8–40.5] | 30.0 [23.5–43.0] | 0.8965 |
Duration of disease, month | 36.0 [5.5–138.0] | 44.0 [11.5–93.0] | 0.7081 |
Hospitalization - n (%) | 27 (50.0) | 22 (48.9) | 1.0000 |
CDAI | 260 [235–310] | 259 [224–320] | 0.9300 |
Disease location - n (%) | |||
Colon | 23 (42.6) | 17 (37.8) | 0.6838 |
Ileum and colon | 31 (57.4) | 28 (62.2) | 0.6838 |
Surgical history – n (%) | 13 (24.1) | 15 (33.3) | 0.3724 |
Previous biologics treatment - n (%) | 10 (18.5) | 10 (22.2) | 0.8022 |
Concomitant medication - n (%) | |||
5-Aminosalicylates | 46 (85.2) | 37 (82.2) | 0.7865 |
Corticosteroids | 8 (14.8) | 8 (17.8) | 0.7865 |
Azathioprine | 7 (13.0) | 9 (20.0) | 0.4157 |
6-Mercaptopurine | 3 (5.6) | 2 (4.4) | 1.0000 |
Nutrition therapy – n (%) | 37 (68.5) | 31 (68.9) | 1.0000 |